Eikon Therapeutics, Inc. (EIKN) Financial Statements

13 Followers

Eikon Therapeutics, Inc. Financial Overview

Eikon Therapeutics, Inc.'s market cap is currently $520.27M. The company's EPS TTM is $; its P/E ratio is -3.20; Eikon Therapeutics, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25
Income Statement
Total Revenue	$ 0.00
Gross Profit	$ -24.18M
Operating Income	$ -338.94M
EBITDA	$ -299.24M
Net Income	$ -324.25M
Balance Sheet
Cash & Short-Term Investments	$ 335.98M
Total Assets	$ 594.73M
Total Debt	$ 257.32M
Net Debt	$ 152.42M
Total Liabilities	$ 1.47B
Stockholders' Equity	$ -879.03M
Cash Flow
Free Cash Flow	$ -235.26M
Operating Cash Flow	$ -188.52M
Investing Cash Flow	$ -181.34M
Financing Cash Flow	$ 352.05M

Currency in USD

Eikon Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Eikon Therapeutics, Inc. Debt to Assets

Balance Sheet >

Eikon Therapeutics, Inc. Cash Flow

Cash Flow >

Eikon Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >